

#### IV. Response to Comments

Because of the large number of items of correspondence we normally receive on **Federal Register** documents published for comment, we are not able to acknowledge or respond to them individually. We will consider all comments we receive, and, if we proceed with a subsequent document, we will respond to the major comments in the preamble to that document.

#### V. Regulatory Impact Statement

This notice does not require an impact analysis because it does not have an economic impact on small entities, small rural hospitals, or State, local, or tribal governments.

In accordance with the provisions of Executive Order 12866, this notice was not reviewed by the Office of Management and Budget.

(Catalog of Federal Domestic Assistance Program No. 93.778, Medical Assistance Program)

(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: September 7, 2001.

**Thomas A Scully,**

*Administrator, Centers for Medicare & Medicaid Services.*

[FR Doc. 01-27700 Filed 11-1-01; 8:45 am]

BILLING CODE 4120-01-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### Administration for Children and Families

[Program Announcement No. ACYF-PA-HS-02-01A]

##### Discretionary Announcement of the Availability of Funds and Request for Applications for Select Service Areas of Early Head Start; Correction

**AGENCY:** Administration for Children, Youth and Families, ACF, DHHS.

**ACTION:** Correction.

**SUMMARY:** This document contains a correction to the Notice that was published in the **Federal Register** on September 20, 2001.

On page 48475, Appendix A, Part II, in the State of Missouri, in the County of St. Charles, in the FY 2002 funding level column, delete “1,470,549” and add “1,497,549”.

On page 48476, Appendix A, Part II, in the State of New York, in the County of Bronx, in the FY 2002 funding level column, delete “1,334,471” and add “1,322,291”. In the State of New York,

in the County of Cattaraugus, in the FY 2002 funding level column, delete “468,962” and add “511,079”. In the State of New York, in the County of Cattaraugus, in the FY 2002 funding level column, delete “450,808” and add “568,205”. In the State of New York, in the County of Chenango, in the FY 2002 funding level column, delete “468,962” and add “511,079”. In the State of New York, in the County of Monroe, in the FY 2002 funding level column, delete “1,995,614” and add “2,173,928”. In the State of New York, in the County of Rensselaer, in the FY 2002 funding level column, delete “670,221” and add “732,234”. In the State of New York, in the County of Steuben, in the FY 2002 funding level column, delete “329,700” and add “349,700”. In the State of New York, in the County of Westchester, in the FY 2002 funding level column, delete “941,224” and add “1,033,799”. In the State of New York, in the County of Erie, in the FY 2002 funding level column, delete “1,277,058” and add “1,381,901”. In the State of New York, in the County of Schenectady, in the FY 2002 funding level column, delete “1,057,663” and add “743,672”.

**FOR FURTHER INFORMATION CONTACT:** The ACYF Operations Center at 1-800-351-2293 or send an e-mail to [ehs@lcn.net](mailto:ehs@lcn.net). You can also contact Sherri Ash, Early Head Start, Head Start Bureau at (202) 205-8562.

Dated: October 29, 2001.

**James A. Harrell,**

*Acting Commissioner, Administration on Children, Youth and Families.*

[FR Doc. 01-27610 Filed 11-1-01; 8:45 am]

BILLING CODE 4184-01-M

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### Food and Drug Administration

[Docket No. 01N-0336]

##### Schering Corp. et al.; Withdrawal of Approval of 51 New Drug Applications and 25 Abbreviated New Drug Applications; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of August 16, 2001 (66 FR 43017). The document announced the withdrawal of approval of 51 new drug applications (NDAs) and 25 abbreviated new drug applications (ANDAs). The document inadvertently withdrew

approval of NDA 17-255 for DTPA (chelate) Multidose (kit for the preparation of Tc-99m pentetate injection) held by Nycomed Amersham Imaging, 101 Carnegie Center, Princeton, NJ 08540. FDA confirms that approval of NDA 17-255 is still in effect.

**EFFECTIVE DATE:** August 16, 2001.

**FOR FURTHER INFORMATION CONTACT:**

Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

In FR Doc. 01-20605 appearing on page 43017 in the **Federal Register** of Thursday, August 16, 2001, the following correction is made: On page 43018, in the table, the entry for NDA 17-255 is removed.

Dated: October 11, 2001.

**Janet Woodcock,**

*Director, Center for Drug Evaluation and Research.*

[FR Doc. 01-27520 Filed 11-01-01; 8:45 am]

BILLING CODE 4160-01-S

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### Food and Drug Administration

[Docket No. 01N-0494]

##### Prescription Drug Products; Doxycycline and Penicillin G Procaine Administration for Inhalational Anthrax (Post-Exposure)

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is clarifying that the currently approved indications for doxycycline and penicillin G procaine drug products include use in cases of inhalational exposure to *Bacillus anthracis* (the bacterium that causes anthrax). We also are providing dosing regimens that we have determined are appropriate for these products for this use. We encourage the submission of supplemental new drug applications (labeling supplements) to add the dosage information to the labeling of currently marketed drug products.

**ADDRESSES:** Submit labeling supplements to the Center for Drug Evaluation and Research, Food and Drug Administration, Central Document Room, 12229 Wilkins Ave., Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:**

Dianne Murphy, Center for Drug Evaluation and Research (HFD-950),